Interojo Inc. (119610.KQ) - Deep Dive Research Report

KOSDAQ-listed contact lens manufacturer | Healthcare / Medical Devices | Report date: 2026-06-15

Section 1: What the Company Does

Interojo makes contact lenses. That is the whole business, and it is worth stating plainly because the company does it across the entire value chain - it formulates its own lens materials, designs the molds, runs the cast-molding production lines, sterilizes and packs the finished product, and then sells it two ways: under its own consumer brand, Clalen (클라렌), and as an OEM/ODM contract manufacturer that produces lenses to other companies' specifications for sale under their labels in more than 60 countries.

The company was founded in 2000 in Pyeongtaek, Gyeonggi Province, by Noh Si-chul (노시철), who remains chairman and the controlling shareholder today. It listed on KOSDAQ on 28 July 2010 at an offering price of 12,000 won per share. It is the only pure-play contact lens manufacturer listed on a Korean exchange.

The core value proposition is straightforward. Contact lenses are a high-volume, low-unit-price, regulated medical device where the hard part is not the idea but the manufacturing: doing it cheaply, consistently, at clinical-grade quality, and at scale. Interojo's pitch to its OEM/ODM customers is that a Korean manufacturer can produce silicone hydrogel and color/cosmetic lenses at a cost and quality that lets a distributor in Europe, the Middle East, China or Japan compete against the four Western incumbents (Johnson & Johnson, Alcon, CooperVision, Bausch + Lomb) without building a factory. To Korean and East Asian consumers, the pitch is the Clalen brand - particularly color and cosmetic "beauty" lenses that ride the global popularity of K-beauty and K-pop aesthetics.

The technical difficulty is real and is the reason the business is defensible. Making a contact lens that a regulator will approve requires controlling the polymer chemistry (water content, oxygen permeability, surface wettability), the optical geometry to micron tolerances, and a sterile, validated production process - and then proving "substantial equivalence" to existing approved devices in clinical trials before you can sell in a regulated market. Silicone hydrogel, the high-oxygen-permeability material that now dominates the premium end of the market, is materially harder to make than older hydrogel because silicone is hydrophobic and must be surface-treated to be comfortable on the eye. Interojo spent years developing its own silicone hydrogel formulations and its proprietary "Grab-su Plus" (그랩수 플러스) surface process; this is the technology it is now using to push into the United States.

A concrete walk-through of what Interojo actually does: a European distributor wants a private-label daily-disposable color lens line. Interojo's R&D team formulates the lens material and tint, designs the cast-molding tooling, runs validation and any required clinical/regulatory documentation, then mass-produces the lenses at its Pyeongtaek factories, blister-packs and sterilizes them, prints the distributor's branding, and ships in bulk. The distributor sells them through opticians and online. Interojo never touches the end consumer in that transaction - it is the factory behind the brand. In parallel, the same plant runs Clalen-branded product for Korean optical shops and Interojo's own export markets.

The single most important fact about the last three years is that this is a company that nearly died not from its product but from its accounting and its owner's balance sheet. In 2024 its auditor refused an opinion, its stock was suspended, and it came within a regulatory step of delisting. Everything in this report should be read against that backdrop.

Section 2: Business Segments

Interojo is effectively a single-business company - it makes contact lenses - but it is useful to think about it along two axes that management itself reports against: channel/brand (own-brand Clalen vs. OEM/ODM) and geography (domestic Korea vs. overseas export). It does not report cleanly separable financial segments the way a conglomerate would, so I treat these as the two meaningful divisions of one business rather than as standalone segments.

Own-brand (Clalen) and domestic distribution

Clalen is Interojo's proprietary brand, dominant in the Korean market and recognized across East Asia. Domestically, Interojo sells through Korea's optical-shop network. In 2025 management restructured this domestic channel heavily, expanding a franchised optical-shop distribution arrangement (referred to in disclosures as the "Family Shop" system) from 428 affiliated stores to roughly 1,708, which by the third quarter of 2025 reportedly accounted for around 85% of the relevant domestic channel sales. The core capability here is brand equity plus a controlled distribution footprint that keeps shelf space and pricing discipline. Domestically Interojo holds roughly a 25% share of an approximately 480 billion won Korean contact-lens market.

Domestic sales are the smaller and slower-growing side of the business: in Q1 2026 domestic revenue was 6.7 billion won, about 22% of the total, growing 24% year over year off a recovering base.

OEM/ODM and overseas export

This is the growth engine and the larger part of the company - overseas sales were 24 billion won in Q1 2026, 78% of total revenue. Interojo manufactures to the specifications of overseas distributors and brand owners and exports to more than 60 countries. The core capability is low-cost, high-quality, clinically-validated manufacturing at scale, plus the regulatory documentation to clear products into multiple jurisdictions. This is what took 15+ years to build and what a new entrant cannot replicate quickly: an installed base of approved products with overseas partners, validated production lines, and the silicone-hydrogel material science.

Within overseas, the regional mix is shifting fast. In Q1 2026 Europe/CIS was the largest and fastest-scaling region (8.7 billion won, +67% year over year), with the Middle East (+111%) and China (+100%) growing even faster off smaller bases, and Japan an established market. The United States is the strategic option not yet in the numbers - pending FDA clearance.

Section 3: Products and Business Detail

Product catalogue. Interojo's range spans essentially the full contact-lens spectrum: silicone hydrogel lenses (the premium, high-oxygen-permeability category), conventional hydrogel and sodium-hyaluronate lenses, frequent/regular-replacement lenses, daily disposables, toric lenses (for astigmatism), multifocal lenses (for presbyopia), color and cosmetic "beauty" lenses, therapeutic/bandage lenses, rigid gas-permeable (RGP) hard lenses, and lens-care solutions. Recent Clalen launches illustrate where the company is pushing: the Clalen O2O2 1-Day family of silicone-hydrogel daily disposables, including a toric (astigmatism-correcting) silicone daily and color variants, built on the proprietary "Grab-su Plus" surface-treatment process.

The product mix is migrating toward silicone hydrogel deliberately, because that is where both the growth and the margin are. In Q1 2026 silicone hydrogel products generated 6 billion won, about 20% of revenue, up 11 percentage points year over year - management has stated a medium-term target of lifting silicone to roughly 30% of sales. Clear (non-color) lenses were 11.7 billion won (+43%) and regular-replacement lenses 11.1 billion won (+43%) in the same quarter.

Technical and regulatory specifications that matter. A contact lens is a Class II/III medical device in most jurisdictions. Selling in a new market requires the local clearance: a CE mark in Europe, country registrations across the Middle East and Asia, and in the United States an FDA 510(k) clearance demonstrating "substantial equivalence" to a legally marketed predicate device. For its US push, Interojo ran a randomized clinical trial of its monthly-replacement silicone hydrogel lens (material name Inofilcon A) across three US sites with 75 participants over three months; the trial showed substantial equivalence in safety and effectiveness to a competitor predicate (comparable adverse-event rates, no meaningful differences in visual acuity, corneal response or comfort). Interojo planned to file its 510(k) in early 2026. The process knowledge - polymer formulation, surface treatment, micron-tolerance optics, validated sterile cast-molding - is the moat.

Manufacturing. Production is concentrated in Korea, with three factories in the Pyeongtaek area. The dominant production method is cast molding (each lens molded individually), which is the cost-efficient high-volume process used for disposables. A central operational story of 2025-2026 is yield: production yield improved from about 62% in 2024 to roughly 77% by March 2026, with management/analysts pointing to the high-80s as the next target. Because contact-lens manufacturing is high fixed cost, every point of yield improvement drops to operating profit, which is why operating margin expanded so violently in 2025-2026 even on modest revenue growth.

Geographies and milestones. Founded 2000; KOSDAQ IPO 2010; selected into the Korean government's "World Class 300" global-growth program (a recognition reserved for mid-sized firms with export-scaling potential); exports to 60+ countries. The pending US FDA 510(k) clearance would be the next major milestone - the company has described US approval as a gateway not only to the US but to Latin America and the Middle East, where US clearance carries regulatory weight.

Section 4: Customers

There are two distinct customer types, and they buy for different reasons.

OEM/ODM distributors and brand owners (the larger, overseas side). These are contact-lens distributors and brand companies across Europe/CIS, the Middle East, China, Japan and elsewhere who want product to sell under their own labels without owning a factory. Inside these customers, the buying decision sits with procurement and product-management leadership, and the criteria are price, quality consistency, the breadth of the catalogue (can one supplier provide silicone dailies, color, toric and multifocal?), and - critically - whether Interojo already holds the regulatory approvals to ship into that customer's market. The sales cycle is long and relationship-driven: qualifying a contact-lens supplier means validating the product clinically and registering it with the local regulator, which can take many months to over a year. Management explicitly attributed the Q1 2026 strength to "stable supply relationships with major overseas partners," which is the tell that this is a repeat, relationship-based business rather than spot trading.

Korean and East Asian consumers via the Clalen brand (the domestic side). Here the real customer is the optical shop / optician that stocks Clalen, and the end buyer is the consumer choosing a beauty or vision lens. The optician's decision rests on margin, brand pull (does the consumer ask for Clalen?), and supply reliability. Interojo's franchised "Family Shop" expansion is a direct attempt to lock in this channel.

Switching costs. They are real but asymmetric. Once an OEM customer has qualified an Interojo product - run the clinical/registration work, printed packaging, built the SKU into their catalogue - moving to another factory means re-qualifying and re-registering, which is costly and slow. That creates installed-base stickiness. On the domestic consumer side, switching costs are low (a consumer can change brands at the next purchase), which is why brand and channel control matter so much.

Concentration and contract structure. Public disclosure does not break out named customer concentration, and Interojo has not flagged a single dominant customer. The overseas business appears to be a portfolio of distributor relationships across many countries, which diversifies risk - the rapid simultaneous growth in Europe/CIS, Middle East and China in Q1 2026 suggests breadth rather than dependence on one account. Contracts are supply relationships rather than disclosed long-term take-or-pay agreements, so revenue predictability comes from the stickiness of qualified products and repeat ordering rather than from contracted minimums.

Section 5: Competitive Landscape

The global contact-lens industry is an oligopoly at the top. Four Western incumbents - Johnson & Johnson Vision (Acuvue), Alcon (Dailies/Precision), CooperVision, and Bausch + Lomb - together dominate the premium daily-disposable and silicone-hydrogel categories that drive industry profit. J&J alone is often cited around a 12% global share, with the top four plus EssilorLuxottica and Menicon collectively holding roughly a third of a moderately fragmented market. Interojo does not compete head-on with these giants in their core branded daily-disposable strongholds; it competes one tier down and around the edges - as the OEM/ODM factory behind regional brands, and in the color/cosmetic and value silicone segments where the Western majors are less focused.

Where Interojo wins: cost. A Korean cast-molding manufacturer can undercut Western incumbents on private-label and value silicone, and Interojo has the catalogue breadth (color, toric, multifocal, silicone daily) to be a one-stop OEM partner. Where it loses: brand and the premium-daily franchise. It cannot out-market Acuvue to a Western consumer, and in regulated premium markets (notably the US) it has historically lacked the clearances the incumbents enjoy - which is exactly what the FDA 510(k) effort is meant to fix.

Its most direct domestic peer is StarVision and its manufacturing subsidiary Geo Medical, whose OLENS brand is strong in color/cosmetic lenses and has expanded internationally (e.g., into Japan's Don Quijote retail chain). In the color/beauty niche that rides K-culture, this is the company Interojo most directly fights.

Approximate market caps are peer-size references only, in the currencies shown, as of June 2026, and move continuously.

Barriers to entry are moderate-to-high and rising with the silicone shift. A new entrant must master polymer chemistry and silicone surface treatment, build validated sterile production lines, and clear regulatory approvals market by market - years of work and capital. But the barriers are not insurmountable for a well-funded regional player, and the value/color end of the market is more competitive and more commoditized than the premium-daily end. Interojo's defensibility comes from its installed base of approved OEM products, its catalogue breadth, and its cost position - not from any single patented blockbuster.

Section 6: Industry

Demand drivers. Contact-lens demand is driven by global myopia prevalence (rising, especially in East Asia), the secular shift from spectacles to lenses and within lenses from reusables to daily disposables, the aging-population shift toward multifocal lenses, and - for the color/cosmetic segment Interojo plays in heavily - fashion and beauty trends amplified by K-pop and K-beauty cultural reach. These are slow, durable tailwinds rather than cyclical swings.

Size and growth. Estimates vary by research house, but the global contact-lens market is in the low-to-mid tens of billions of US dollars (commonly cited around US$12B for "contact lenses" narrowly and ~US$20B for broader disposable definitions), growing mid-single digits. The silicone hydrogel sub-segment - Interojo's strategic target - was valued around US$8.7B in 2025 and is projected toward ~US$14B by 2033 at roughly a 6.8% CAGR, with daily-disposable silicone the largest and fastest-growing slice. The Korean domestic market is roughly 480 billion won. (Sources: Grand View Research, GM Insights, Dataintelo, Fortune Business Insights.)

Position in the supply chain. Interojo sits as a manufacturer/OEM - upstream of brands and distributors, downstream of raw-material (monomer/polymer) suppliers. For many regional brands it is the supply chain.

Regulation. This is a regulated medical-device industry. Each market requires its own clearance: FDA 510(k) in the US, CE marking in the EU, and national registrations elsewhere. Regulation is itself a barrier and a moat - and the gating item for Interojo's US ambition.

Cyclicality. Contact lenses are a consumable medical/vision necessity for users, so end demand is relatively defensive across economic cycles. Interojo's own results, however, have been volatile - but that volatility has come from company-specific factors (the accounting restatement, inventory issues, yield, FX and channel restructuring) rather than from industry cyclicality.

Tailwinds and headwinds. Industry tailwinds: the silicone and daily-disposable mix shift, East Asian myopia, and K-beauty-driven color demand. Headwinds: the four Western incumbents' scale and marketing power, price competition in the value/color OEM tier, and FX sensitivity given the heavily export-weighted revenue base.

Section 7: Growth Triggers

Sourcing note: Interojo does not hold English-language earnings calls or publish concall transcripts. The triggers below are drawn from the company's five most recent quarterly earnings disclosures and the management commentary accompanying them (Q1 2025, Q2 2025, Q3 2025, Q4/FY2025, Q1 2026), plus directly-quoted analyst notes citing management. Each is dated to its reporting period.

• US FDA 510(k) clearance for silicone hydrogel lenses (filing early 2026; clearance expected ~mid-2026). Successful completion of the US clinical trial (Inofilcon A monthly silicone lens) was announced around the Q4/FY2025 reporting window (Jan 2026); management planned to file the 510(k) within weeks. Kiwoom Securities, citing management, expected clearance around May 2026 (Q1 2026 reporting, May 7 2026). Repeated across multiple periods - this is the single most-cited forward catalyst. As of this report, clearance had not been independently confirmed; treat it as pending.

Kiwoom (May 7 2026), paraphrasing management guidance: FDA 510(k) approval for the clear silicone-hydrogel frequent-replacement lens is anticipated around May, expected to "accelerate growth in existing markets like China and Japan" as well as open the US.

• Silicone hydrogel mix expansion toward ~30% of sales. Stated repeatedly (Q3 2025 and Q1 2026). Silicone was ~20% of revenue in Q1 2026, up 11 points year over year; management's medium-term target is ~30%. This is the margin-mix lever.

• Production yield ramp from ~77% toward the high-80s. Disclosed in the Q1 2026 reporting (May 7 2026): yield rose from ~62% (2024) to ~77% (March 2026). Each further point of yield improves operating leverage on a high-fixed-cost cost base.

• Geographic expansion in high-growth regions - Europe/CIS, Middle East, China. Q1 2026 reporting (May 7 2026) flagged Europe/CIS +67%, Middle East +111%, China +100% year over year, attributed to "stable supply relationships with major overseas partners." Management framed these as continuing growth corridors.

• Domestic channel build-out via the franchised "Family Shop" optical-store network. Q3 2025 reporting noted expansion from 428 to ~1,708 affiliated stores, becoming the dominant domestic channel (~85% of relevant sales). Forward driver for domestic premiumization.

• New silicone daily-disposable product launches (Clalen O2O2 1-Day family, incl. silicone toric and color). Launched through 2024-2025 and rolling out through national optical-shop placement; cited as the vehicle for the silicone-mix and domestic-premium triggers.

• Direct-to-consumer / retail (pop-up store) channel expansion. Q1 2026 reporting (May 7 2026) cited offline pop-up store initiatives and DTC expansion as a medium-term growth and profitability lever.

Section 8: Key Risks

Governance and controlling-shareholder distress (high probability, high severity). This is the dominant risk and it is specific to Interojo. Chairman Noh Si-chul and his family have pledged effectively their entire holding (around 35%) as collateral for stock-backed loans, refinanced in 2025 with Stick Credit at roughly 9% interest. In August 2025 the family agreed to sell 1.13 million shares to Ascent PE at 35,000 won (a ~2x premium to the then ~18,000-19,000 market price); the deal collapsed in September 2025, and in December 2025 a court granted Ascent PE a provisional attachment (가압류) over the family's entire 34.98% stake (4.299 million shares), with breach-of-warranty litigation a live possibility. The mechanism that hurts shareholders: if the owner's loans are called or the litigation forces a distressed disposal of the pledged block, control could change hands chaotically, and the company's capital-allocation decisions (notably the abnormally high dividend) appear partly driven by the owner's personal liquidity needs rather than by the business. This is a structural overhang, not a tail risk.

Accounting credibility and internal controls (moderate probability, high severity). In 2024 the auditor (Samil/PwC) refused/qualified its opinion over inventory (~47 billion won questioned) and weak internal controls; trading was suspended; FY2023 figures were restated sharply downward (operating profit cut from 18.3 to 6.6 billion won, net income from 13.4 to 4.1 billion won). A clean opinion was obtained in June 2024 and trading resumed, but the episode revealed real control weaknesses. The mechanism: any recurrence - or investor memory of the last one - depresses the multiple investors are willing to assign and raises the cost of capital. Management has cited resolution of the inventory and audit issues as a turnaround pillar, which is itself an admission of how serious it was.

Dilution from convertible preferred (RCPS) (moderate probability, moderate severity). In September 2025 Interojo issued 30 billion won of redeemable convertible preferred shares (1.49 million shares at 20,088 won) to Stick Prism. On conversion this adds roughly 12% to the common share count, partly offsetting the 6.6% reduction from the 2025 treasury-share cancellation. The mechanism: per-share value dilution and a preferential-dividend claim ahead of common holders.

FX and export concentration (moderate probability, moderate drag). With ~78% of revenue overseas and production costs in won, the heavily-exported revenue base is sensitive to the won/USD and won/EUR rates. A sharp won appreciation compresses reported revenue and margin even if volumes hold.

Execution risk on the US/FDA catalyst (moderate probability, moderate severity). Much of the bull narrative rests on FDA 510(k) clearance and the silicone mix shift. If clearance slips or the US launch under-delivers against expectations management and analysts have set, the re-rating thesis weakens. This is an expectations risk more than a survival risk.

Competitive pressure in the value/color OEM tier (ongoing, moderate drag). The color/cosmetic and value-silicone segments where Interojo competes are more commoditized than the premium-daily franchise, and StarVision/Geo Medical (OLENS) competes directly in the K-beauty color niche, capping pricing power.

Section 9: Walk the Talk

The five reporting periods used: Q1 2025 (reported May 2025), Q2 2025 (reported Aug 2025), Q3 2025 (reported Nov 2025), Q4/FY2025 (reported ~Jan-Feb 2026), and Q1 2026 (reported May 7 2026). The most recent is within ~40 days of this report. Caveat: Interojo does not host earnings calls with transcripts; this assessment is built from the quarterly disclosures and the management commentary and analyst notes attached to them, which is the credible-record equivalent for this issuer.

The honest starting point is that management's credibility was shattered in 2024 and has been under reconstruction since. The 2023 restatement and the 2024 audit-opinion refusal mean any "walk the talk" exercise begins from a deficit, not a clean slate. With that framing, the through-2025-2026 record is genuinely better than the prior period.

Through 2025, the recurring promise was operational normalization: resolve the inventory and audit issues, restore governance, and rebuild profitability through yield and mix rather than top-line heroics. On the audit and listing front, this was delivered - the clean opinion came in June 2024 and trading resumed, exactly as needed to survive. On profitability, the delivery has been concrete and measurable: operating profit grew every quarter through 2025 on a year-over-year basis (Q2 2025 +373%, Q3 2025 +19%) even as revenue was roughly flat-to-down (9-month 2025 revenue was -7% year over year), which is precisely the "margin before growth, via yield and mix" story management told. By Q1 2026, both lines fired together - revenue +33%, operating profit +186%, net income +252% - which is the first quarter where the turnaround narrative was backed by growth and not just cost.

The yield guidance has tracked. Management/analysts pointed to yield moving from ~62% (2024) to ~77% (March 2026) on the path to the high-80s; the margin expansion is consistent with that being real rather than rhetorical. The silicone-mix promise is also tracking, if early: silicone reached ~20% of sales in Q1 2026 (up 11 points) against a ~30% medium-term target - directionally delivered, not yet complete.

Repeated guidance (Q3 2025 and Q1 2026): lift silicone hydrogel toward ~30% of revenue via differentiated new products and chain-distribution growth.

Outcome: silicone moved from single digits toward 20% within the window - credible progress, not yet the target.

Where the talk and the walk diverge sharply is governance and capital allocation. Management has spoken the language of "active enhancement of shareholder value" - the 15 billion won treasury buyback (executed mid-2025, ~867,696 shares cancelled in August 2025) and the elevated dividend are presented as shareholder-friendly. But the same window saw the controlling family attempt to sell shares to a PE buyer at a 2x premium, the deal collapse, a 30 billion won dilutive RCPS issuance, family-wide stock-backed loans at 9%, and a court attachment over the entire family stake. The abnormally high 2024 dividend payout (over 2,000% of that year's depressed earnings) sits uncomfortably alongside an owner under acute personal financial pressure. So the operational promises have largely been kept; the governance signals are mixed at best and, on capital allocation, point to decisions shaped by owner liquidity needs rather than purely by minority-shareholder interest.

Assessment: on the operating business, this is management that has, since mid-2024, broadly done what it said - the recovery is real and the numbers corroborate the commentary. On governance and capital allocation, the controlling-shareholder situation makes management's "shareholder value" language unreliable as a guide to minority outcomes. Trust the operating turnaround; do not assume capital-allocation decisions are made for minority shareholders first.

Section 10: Shareholder Friendliness Index

Dividends. Interojo has paid a dividend for 16 consecutive years, and the recent trend is up but distorted. For FY2025 the company declared 650 won per share, totaling about 8.3-8.4 billion won, a payout ratio of roughly 64% on FY2025 net income (~12.9-14.3 billion won) - a normal, healthy payout. For FY2024, however, the total dividend was about 3.8 billion won against near-zero reported net income, producing an abnormal payout ratio reported above 2,000%. The reason is unusual and worth stating: the controlling family is under heavy personal financial pressure (stock-backed loans at ~9%), and analysts and press have linked the elevated dividend directly to the owner's liquidity needs rather than to ordinary earnings-based distribution policy. So the dividend "growth" is real in won terms (+~120% FY2024→FY2025) but its quality is compromised by who needs the cash.

Buybacks and dilution. Buybacks: a 15 billion won (≈150억) treasury program was executed in 2025 - the company purchased about 602,410 shares between 14 May and 12 August 2025 and then cancelled approximately 867,696 treasury shares on 13 August 2025, reducing shares outstanding from 13,216,478 to 12,348,782, a 6.6% reduction. That is a genuine, completed buyback-and-cancellation, well-timed during the post-suspension recovery. (This older-than-90-day program was verified via Korean exchange disclosures and financial news, not from any database block.) Offsetting it, in September 2025 the company issued 30 billion won of convertible preferred shares (1.49 million RCPS at 20,088 won) to Stick Prism, which on conversion would expand the common count by roughly 12% and carries a preferential dividend. Net effect over the period: common shares were reduced ~6.6% via the cancellation, but a material convertible-preferred overhang now exists that could more than reverse that on conversion.

Verdict: Neutral, leaning conflicted. The company genuinely returns capital (real buyback-and-cancellation, a 64% FY2025 payout), but the capital-return pattern is entangled with the controlling shareholder's personal financial distress and partly offset by dilutive preferred issuance - so the friendliness is to the owner's balance sheet as much as to minority holders.

Section 11: Insider Activities

For South Korea, the primary source is DART (dart.fss.or.kr) "임원·주요주주 특정증권등 소유상황보고서" (Officer & Major Shareholder Holdings Reports) and 5%-rule filings. The portal is partly accessible, but the material transactions over the last 12 months are large controlling-shareholder events that were also reported in detail through Korean exchange disclosures and press; I cite those disclosure dates. There is no evidence of routine open-market individual insider buying in the period - the insider story here is the controlling family's distress and a corporate buyback, not conviction purchases.

Buys - read the signal. There were no open-market conviction purchases by individual directors or officers in the window. The only "buying" was the company's own treasury buyback - shareholder-friendly in isolation and well-timed, but a corporate-finance action, not an insider expressing personal conviction with personal cash. There is no cluster-buy signal here.

Sells - work out the why. The controlling family's attempted 1.13 million-share sale to Ascent PE (Aug 2025) was a deliberate, premium-priced disposal by the owner - the stated context is the family's heavy debt load and pledged shares, i.e., a liquidity-driven exit attempt, not a routine diversification. It collapsed in September 2025; the family then took on more secured debt (Stick Credit) and the company raised dilutive preferred capital. The December 2025 court attachment over the entire family stake is the opposite of an insider-confidence signal.

Net assessment. Insiders are, in substance, net would-be sellers under financial duress, not buyers. Activity is concentrated overwhelmingly in one party - the controlling family - whose entire stake is pledged, who tried and failed to sell at a premium, and who is now subject to a court attachment and potential litigation. The company-level buyback partially offsets the optics but does not change the read. This is a red flag on the governance/ownership axis: the controlling shareholder's personal balance sheet, not business conviction, is driving insider-level capital flows. It does not impugn the operating turnaround, but it materially raises the risk that ownership and control could change in a disorderly way.

Section 12: Scenarios

Bull case. The FDA 510(k) clearance lands in 2026 and Interojo's silicone hydrogel lenses gain a foothold in the United States - and, just as importantly, US clearance becomes a credibility passport that accelerates registrations and orders across Latin America and the Middle East. The silicone mix climbs past 30% of sales, production yield reaches the high-80s, and the operating leverage that drove Q1 2026's 186% profit jump compounds as volume scales on a fixed cost base. Europe/CIS, the Middle East and China keep growing at the double-and-triple-digit rates seen in early 2026 as OEM partners deepen their orders. On the ownership side, the cleanest version of the bull case is that the controlling-shareholder mess resolves - the litigation settles, a new strategic or financial owner takes the pledged block at a fair price, and the overhang lifts, allowing the stock to re-rate to reflect the genuinely improved operating business. A normalized, well-governed Interojo with a US franchise and a 30%+ silicone mix is a structurally more valuable company than the one that nearly delisted in 2024.

Base case. Management keeps doing roughly what it has done since mid-2024: grind yield higher, shift mix toward silicone, defend the domestic franchise channel, and grow the overseas OEM book at a healthy clip. FDA clearance arrives but the US ramp is gradual rather than explosive - meaningful optionality, not an overnight step-change. Margins stay structurally higher than the pre-crisis level because the yield and mix gains are real and durable. The dividend continues, the RCPS sits as a known dilution overhang, and the controlling-shareholder situation muddles along - the loans get serviced, the litigation drags without forcing a fire sale, and the governance discount persists but doesn't worsen. This is a steadily improving operating business carrying a permanent governance asterisk.

Bear case. The owner's balance sheet breaks before the business fully heals. The Ascent PE litigation goes against the family or the Stick Credit loans come under pressure, the pledged 35% block is forced into a disorderly sale or the attachment crystallizes, and control changes hands chaotically - paralyzing strategy and capital allocation just as the operating turnaround needs steady hands. Compounding it, the accounting credibility never fully recovers in investors' minds; a single inventory or control hiccup reopens the 2024 wound. Operationally, FDA clearance slips or the US launch disappoints, the silicone mix stalls below target, a strong won compresses the heavily-exported margin, and OLENS/Geo Medical and the Western incumbents squeeze pricing in the value and color tiers. The RCPS converts and dilutes just as growth slows. In the worst version, a good little manufacturer is undone not by its lenses but by its owner.

Sourcing transparency: Interojo does not publish earnings-call transcripts; the five "reporting periods" used are its quarterly DART/exchange disclosures and the management commentary attached to them. No SemiAnalysis, Stratechery, or MBI Deep Dives coverage of Interojo exists, so the optional "Further Reading" section is omitted. Several financial figures carry consolidated-vs-separate-basis noise in Korean small-cap reporting and are presented as best-reconciled approximations; the FY2024 near-zero net income and the FDA clearance status in particular should be verified against the primary DART filings before relying on them.

Sources: KED Global - FDA entry; MoneyToday Q1 2026 results; Edaily Q1 2026 OP; FN News - Kiwoom turnaround note; Edaily Q3 2025; DigitalToday Q2 2025; DRCR - "saved from the cliff edge"; Dealsite - high dividend / owner debt; Etoday - failed Ascent PE sale & attachment; Nate/Etoday - stake sale collapse; Asiae - 15B won treasury cancellation; DigitalToday - buyback purchase; DigitalToday - cancellation & share count; Korean Wikipedia - Interojo; Hankyung - K contact lens / domestic share; Seoul - Clalen O2O2 silicone launch; Grand View Research - market size; GM Insights - market; Interojo IR.

Note: I do not have file-write access in this environment, so the full report is delivered inline above as markdown (copy into Interojo_119610_DeepDive.md), with the chart-data block appended for the chart generator. Quarterly figures carry consolidated-vs-separate-basis noise typical of Korean small-cap reporting; Q4 2025 revenue is derived (FY2025 ~117bn less 9M actuals), and the FDA clearance and FY2024 net-income figures should be confirmed against primary DART filings before relying on them.